A.K.L. Reyners

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

E. M. Dijkgraaf, Saskia J. Santegoets, A.K.L. Reyners et al. · Annals of Oncology · 2015 · 189 citations

Medicine, Immunology, Pathology +6

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

Nielka P. van Erp, Karel Eechoute, A. A. van der Veldt et al. · Journal of Clinical Oncology · 2009 · 183 citations

Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life

Jan J. Meeuse, Yvette M. van der Linden, Geertjan van Tienhoven et al. · Cancer · 2010 · 89 citations

Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension

Karel Eechoute, Astrid A.M. van der Veldt, Sjoukje F. Oosting et al. · Clinical Pharmacology & Therapeutics · 2012 · 85 citations

Hypertension, Genetic Epidemiology, Predict Sunitinib-induced Hypertension +20

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

Eveline M. Dijkgraaf, Saskia J. Santegoets, A.K.L. Reyners et al. · Oncotarget · 2015 · 79 citations · Full text